Table 1.
Different clinicopathological characteristics between BRAF V600E- and V600K-mutant melanoma patients.
Mutation | Frequency (among BRAF V600 Mutations) | DFS | PFS (with TT) | TMB | Response to ICIs |
---|---|---|---|---|---|
V600E | 70–88% | Longer | Longer | Lower | Good |
V600K | 10–20% | Shorter | Shorter | Higher | Better |
DFS: disease-free survival; PFS: progression-free survival; TT: targeted therapy; TMB: tumour mutational burden; ICIs: immune checkpoint inhibitors.